เปรียบเทียบวิธี
ดูวิธีที่เลือกเทียบกันแบบเคียงข้าง แถวที่ต่างกันจะถูกเน้นไว้
| การวิเคราะห์ต้นทุน-ประสิทธิผล (Cost-Effectiveness Analysis - CEA)× | [UNTRANSLATED]× | |
|---|---|---|
| สาขาวิชา | เศรษฐศาสตร์สุขภาพ | เศรษฐศาสตร์สุขภาพ |
| ตระกูล | Process / pipeline | Process / pipeline |
| ปีกำเนิด≠ | 1984 | 1985 |
| ผู้ริเริ่ม≠ | Drummond & Stoddart (Health Economics Research Group, McMaster University) | Alan Williams (Health Economics Research Centre, Oxford University) |
| ประเภท | Method | Method |
| แหล่งต้นตำรับ≠ | Gold, M. R., Siegel, J. E., Russell, L. B., & Weinstein, M. C. (Eds.). (1996). Cost-Effectiveness in Health and Medicine. New York: Oxford University Press. link ↗ | Kind, P. (1989). The EuroQol instrument: an index of health-related quality of life. In B. Teeling Smith (Ed.), Measuring health: a practical approach. Chichester: Wiley. link ↗ |
| ชื่อเรียกอื่น≠ | CEA, ICER, Incremental Cost-Effectiveness Ratio | QALY, health utility measure |
| ที่เกี่ยวข้อง | 5 | 5 |
| สรุป≠ | Cost-effectiveness analysis compares the incremental cost per unit of health benefit gained by one intervention relative to a comparator (standard care or best alternative). Developed rigorously in the 1980s by Drummond, Stoddart, and colleagues, CEA is now the standard framework for technology appraisal globally. NICE, HAS, CADTH, and other health technology assessment bodies use CEA to decide which treatments warrant public funding and at what price. | A QALY measures health benefit as utility weight (0 = death, 1 = perfect health) multiplied by time lived. Developed by Alan Williams in 1985, QALYs enable comparison of disparate health interventions on a common metric. Used globally by health technology assessment bodies—NICE (UK), HAS (France), CADTH (Canada), WHO—to decide which treatments deserve public funding. |
| ScholarGateชุดข้อมูล ↗ |
|
|